This segment focuses on the research, development, and commercialization of novel medicines for the management of various cancers, with a primary emphasis on breast and prostate cancer. Key activities include preclinical studies, clinical trials (Phase 1, 2, and 3), and regulatory submissions for drug approvals. Technologies and methodologies employed encompass targeted therapies, hormonal agents, and immunotherapies. The goal is to improve patient outcomes by providing effective treatment options that address unmet medical needs in oncology. This segment leverages strategic partnerships with universities and other pharmaceutical companies to accelerate drug development and expand market reach. Future opportunities include expanding the pipeline with innovative cancer therapies and exploring new indications for existing drug candidates.

This segment historically focused on the development, manufacturing, and commercialization of the FC2 female condom/internal condom, providing dual protection against unintended pregnancy and sexually transmitted infections. The target market includes ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. While Veru has sold this business, the legacy and expertise in women's health remain relevant. Future opportunities could involve exploring new products or partnerships in women's health, leveraging the company's established distribution channels and market knowledge. This segment also involves regulatory compliance and quality assurance to ensure product safety and efficacy.

This segment is dedicated to the discovery and development of innovative medicines across various therapeutic areas, with a strong focus on oncology. Activities include preclinical research, clinical trials, and regulatory affairs. The segment leverages cutting-edge technologies and methodologies to identify and validate new drug targets, develop novel drug candidates, and conduct clinical studies to evaluate their safety and efficacy. Key therapeutic areas include breast cancer, prostate cancer, and other cancers with unmet medical needs. The goal is to advance promising drug candidates through the clinical development pipeline and obtain regulatory approvals for commercialization. This segment also involves strategic collaborations with academic institutions and other pharmaceutical companies to accelerate drug discovery and development.